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Abstract
Objective: The effects of various weight loss strategies on pancreatic beta cell function remain unclear.
We aimed to compare the effect of intensive lifestyle intervention (ILI) and Roux-en-Y gastric bypass
surgery (RYGB) on beta cell function.
Design: One year controlled clinical trial (ClinicalTrials.gov identiﬁer NCT00273104).
Methods: One hundred and nineteen morbidly obese participants without known diabetes from the
MOBIL study (mean (S.D.) age 43.6 (10.8) years, body mass index (BMI) 45.5 (5.6) kg/m
2, 84 women)
were allocated to RYGB (nZ64) or ILI (nZ55). The patients underwent repeated oral glucose tolerance
tests (OGTTs) and were categorised as having either normal (NGT) or abnormal glucose tolerance
(AGT). Twenty-nine normal-weight subjects with NGT (age 42.6 (8.7) years, BMI 22.6 (1.5) kg/m
2,
19 women) served as controls. OGTT-based indices of beta cell function were calculated.
Results: One year weight reduction was 30 % (8) after RYGB and 9 % (10) after ILI (P!0.001).
Disposition index (DI) increased in all treatment groups (all P!0.05), although more in the surgery
groups (both P!0.001). Stimulated proinsulin-to-insulin (PI/I) ratio decreased in both surgerygroups
(both P!0.001), but to a greater extent in the surgery group with AGT at baseline (P!0.001). Post
surgery, patients with NGT at baseline had higher DI and lower stimulated PI/I ratio than controls
(both P!0.027).
Conclusions: Gastric bypass surgery improved beta cell function to a signiﬁcantly greater extent than
ILI. Supra-physiological insulin secretion and proinsulin processing may indicate excessive beta cell
function after gastric bypass surgery.
European Journal of Endocrinology 164 231–238
Introduction
Obesity is a major risk factor for type 2 diabetes, with
approximately one out of three morbidly obese subjects
(body mass index (BMI)R40 kg/m
2 or BMIR35 kg/m
2
with at least one obesity-related comorbidity) having
type 2 diabetes (1). Reduced insulin sensitivity and beta
cell dysfunction represent the core pathophysiological
defects in type 2 diabetes (2). It is well known that
weight reduction enhances insulin sensitivity in obese
subjects (3), with this contributing to the improvement
in glycaemic control reported after lifestyle intervention
(4) and bariatric surgery (5). By contrast, the
association between weight reduction and restoration
of beta cell function is less clear. Modest weight loss
induced by diet alone (6) or in combination with
exercise (7) in older non-diabetic overweight and obese
subjects has been shown to enhance beta cell function.
Moreover, results from the Diabetes Prevention Pro-
gramme which predominantly included obese, middle-
aged subjects with impaired glucose tolerance (IGT)
indicate improved insulin secretion relative to insulin
sensitivity after 1 year of intensive lifestyle intervention
(ILI) (8). By contrast, 24 months of diet and endurance
exercise did not improve beta cell function in Japanese
Americans with IGT (9). Furthermore, recovery of beta
cell function has been reported after bariatric surgery
(10–12). Increased insulin secretion post surgery could
contribute to high remission rates of type 2 diabetes
after bariatric surgery (5) as well as to postprandial
hypoglycaemia, a phenomenon that has drawn much
attention recently (13, 14).
Given this background, we aimed to compare
in morbidly obese patients without known diabetes
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and Roux-en-Y gastric bypass on beta cell function
as assessed by oral glucose tolerance test- (OGTT)
derived indices.
Methods
Participants and study design
This is an ancillary study to the MOBIL study (Morbid
Obesity treatment, Bariatric surgery versus ILI study,
ClinicalTrials.gov identiﬁer: NCT00273104) (15).I t
includes a subset of 119 morbidly obese participants
without known diabetes who underwent an OGTT
before and after intervention. In addition, 29 normal-
weight (BMI!25 kg/m
2) subjects with normal glucose
tolerance (NGT) served as a control group (data from 27
of these subjects have been published previously (16)).
The MOBIL study aimed to address changes in several
health outcomes related to obesity, with details
concerning the design and intervention published
previously (15). In short, this 1 year controlled clinical
trial included 146 consecutively recruited morbidly
obese subjects predominantly of European descent and
wasconductedatapublictertiarycarecentreinNorway
between December 2005 and June 2009. Patients in the
surgerygroup were allocated to laparoscopic Roux-en-Y
gastric bypass, whereas patients who chose lifestyle
intervention were referred to a rehabilitation centre
specialising in the care of morbidly obese patients
(Evjeklinikken A/S). The 1 year lifestyle programme
aimed to induce a weight loss of at least 10% and
comprised of four stays at the centre lasting for either 1
week or 4 weeks (total 7 week stay). The daily
programme was divided between organised physical
activity (3–4 h) and different psychosocially oriented
interventions. No special diet or weight loss drugs
were prescribed, but patients were encouraged to follow
the guidelines of the Norwegian National Council of
Nutrition.Outsideofthesestays,patientswerecontacted
by phone once every 2 weeks. The patients were
encouraged to self-monitor their eating habits and
physical activity, as well as to visit their general
practitioner regularly.
TheregionalethicscommitteeoftheSouthernNorway
Regional Health Authority approved the study. Written
informed consent was provided by all participants.
Oral glucose tolerance test
A75 gOGTTwasperformedat0800 hafteranovernight
fast, with venous blood samples obtained at 0, 30 and
120 min for determination of serum glucose, insulin,
C-peptide and proinsulin. Treatment with hypoglycaemic
agents was terminated 2 weeks prior to the OGTT for
patientsreceivingsuchtreatment.OnthedayoftheOGTT,
no medications were taken prior to the test.
Glucose tolerance status was determined according to
the criteria of the World Health Organization (17).N G T
was deﬁned as fasting glucose !6.1 mmol/l and 2 h
glucose !7.8 mmol/l. The abnormal glucose tolerance
(AGT, fasting glucose R6.1 mmol/l and/or 2 h glucose
R7.8 mmol/l) groups included subjects with impaired
fasting glucose (IFG), IGT and new onset diabetes
mellitus (NODM). Post challenge hypoglycaemia was
deﬁned as 2 h glucose !2.8 mmol/l.
Calculations
Several estimates of insulin secretion and insulin
sensitivity were initiallyassessed using indices including
the available glucose and insulin measurements from
the OGTT (18–20). However, the insulin sensitivity
indices of Belﬁore et al. (19) and Stumvoll et al. (20),
comprising of glucose and insulin concentrations at
120 min, seemed to overestimate post surgery insulin
sensitivity (signiﬁcantly higher median values than
NGT controls, both P%0.001) and were therefore not
included in the analyses. Consequently, the computer-
based homoeostasis model assessment of insulin
sensitivity (HOMA-S) was preferred as the insulin
sensitivity index (18).
Insulin secretion was estimated using the insulino-
genic index (DIns30/DGluc30,), the ratio of the total area
under the insulin curve to the total area under the
glucose curve (total AUCIns/Gluc) and the Stumvoll ﬁrst
phase index (ﬁrst phaseest: 1283C1.829!Ins30
K138.7!Gluc30C3.772!Ins0) (20). Because insulin
secretion is determined in part by the prevailing insulin
sensitivity, the disposition index (DI), which is the
product of insulin sensitivity and insulin secretion,
yields a better measure of beta cell function (21). Based
on the above-mentioned indices of insulin secretion,
three alternative DIs were calculated.
Circulating proinsulin-to-insulin (PI/I) ratio,
especially stimulated PI/I ratio (22), has previously
been used as an estimate of the beta cell’s ability to
transform proinsulin to insulin. Indeed, elevated PI/I
ratio has been associated with IGT (22) and reduced
insulin secretion (23). PI/I ratios in a fasting and
stimulated state (30 min after glucose ingestion) were
therefore calculated.
Laboratory analyses
HbAlc was analysed using HPLC on Tosoh HLC-723 G7
(Tosoh Corporation, Tokyo, Japan). Serum samples from
the OGTT were separated after 30 min and either stored
at K80 8C or analysed the same day (glucose). Analyses
of glucose were performed using dry reagent slide
technology on the Vitros 950 Analyser until November
2006 and the Vitros FS 5.1 Analyser (Ortho-Clinical
Diagnostics, New York, NY, USA) thereafter. Serum
levels of insulin, C-peptide and proinsulin (Millipore
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RIA. All samples were measured in duplicate, with
serial samples from a given individual run at the same
time. Intra- and inter-assay coefﬁcient of variation were
!10% for all assays.
Statistical analysis
Data are presented as mean (S.D.) or number (%)
unless otherwise speciﬁed. Skewed data were either
transformed using natural logarithms to approximate
normality or analysed using non-parametric tests.
Between-group comparisons were analysed using one-
way ANOVAwith post hoc comparisons (least signiﬁcant
difference, LSD), Mann–Whitney U test, c
2, two-way
ANOVA and analysis of covariance (ANCOVA) including
gender, age, BMI at baseline and baseline value as
covariates. Within-group comparisons between baseline
and follow-up variables were compared using paired
samples t-test. Correlations were calculated with
Pearson’s correlation coefﬁcients. Linear regression
analyses were used to i) explore a potential hyperbolic
relationship between HOMA-S and measures of
insulin secretion (95% CI of the regression coefﬁcient
(b) in the equation ln (insulin secretion)ZconstantC
b!ln (insulin sensitivity) must include K1 and exclude
0) and ii) identify possible predictors of change in DI
and PI/I ratios (age, gender, change in smoking
status (stopped/unchanged/started), family history of
type 2 diabetes (yes/no), glucose tolerance status
(NGT/AGT), change in physical activity (became
inactive/unchanged/became active), treatment choice
(surgery/lifestyle), and percentage weight reduction).
The signiﬁcance level was P!0.05. Statistical
analyses were performed using SPSS 16.0 (SPSS, Inc.,
Chicago, IL, USA).
Results
Baseline characteristics of participants
The 64 patients assigned to gastric bypass were on
average 5 years younger and 13 kg heavier than the 55
patients in the lifestyle groups (both P!0.005).
Otherwise,within the NGTand AGT groups, the surgery
and lifestyle groups were comparable with respect to
gender and measures of glucose homoeostasis (Table 1).
In both the surgery and lifestyle groups, patients with
AGT had higher HbAlc, were less insulin sensitive and
had lower insulin secretion than patients with NGT
(Table 1). In the AGTsurgery group, 9 subjects had IFG,
12 subjects had IGT and 11 subjects had NODM, while
in the AGT lifestyle group, 1 subject had IFG, 10
subjects had IGT and 11 subjects had NODM.
Table 1 Participant characteristics at baseline and at 1-year follow-up. Data are given as mean (S.D.) or n (%). AGT is deﬁned by fasting
glucose R6.1 mmol/l and/or 2 h glucose R11.1 mmol/l.
Normal glucose
tolerance (NGT)
Abnormal glucose
tolerance (AGT)
P for change,
effect of*
Control
(nZ29)
Surgery
(nZ34)
Lifestyle
(nZ33)
Surgery
(nZ30)
Lifestyle
(nZ22)
Treatment
choice
Glucose
tolerance
Age (years) 42.6 (8.7) 39.0 (9.6) 43.2 (11.6) 43.5 (10.3) 51.3 (8.1)
†,‡
Gender (female, yes) 19 (66%) 23 (67%) 24 (73%) 22 (73%) 15 (68%)
BMI (kg/m
2)
Baseline 22.6 (1.5) 47.2 (5.3)
† 43.3 (5.2)
†,‡ 47.3 (6.0)
† 43.5 (4.5)
†,‡
1 year 33.1 (5.1)
s 39.6 (6.3)
s 33.1 (5.4)
s 39.4 (4.0)
s !0.001 0.740
HbAlc (%)
Baseline 5.3 (0.3) 5.2 (0.3) 5.3 (0.3) 5.9 (0.6)
†,§ 5.9 (0.4)
†,§
1 year 5.2 (0.4) 5.3 (0.3) 5.4 (0.3)
s 5.7 (0.5)
s 0.103 !0.001
HOMA-S (%)
Baseline 71.0 (23.9) 32.0 (24.3)
† 31.8 (14.0)
† 21.0 (7.4)
†,§ 23.8 (8.6)
†,§
1 year 67.1 (33.6)
s 43.5 (19.9)
s 60.0 (29.9)
s 33.1 (15.7)
s !0.001 0.793
First phaseest (pM)
Baseline 1348 (455) 2693 (906)
† 2406 (942)
† 2238 (931)
† 2096 (1041)
†,§
1 year 2366 (710)
s 2077 (903)
s 1785 (728)
s 1873 (683) 0.463 0.762
Total AUCIns/Gluc (pmol/mmol)
Baseline 53.1 (22.4) 104.4 (36.6)
† 96.5 (42.8)
† 77.4 (34.6)
†,§ 72.9 (28.1)
†,§
1 year 97.2 (32.7) 78.7 (38.7)
s 70.5 (30.6) 71.0 (26.3) 0.614 0.155
DIns30/DGluc30 (pmol/mmol)
a
Baseline 147 (96) 230 (100)
† 216 (123)
† 144 (99)
§ 119 (62)
§
1 year 256 (139) 249 (167) 172 (153) 149 (111) 0.842 0.993
AUC, area under the curve; Ins, insulin; Gluc, glucose. *P value for the effect of treatment choice and glucose tolerance status at baseline on change in the
variables, two-way ANOVA. Between-group differences at baseline, one-way ANOVA with post hoc comparison (LSD):
†P!0.05 versus control group;
‡P!0.05 versus surgery group in the same glucose tolerance group; and
§P!0.05 versus NGT group in the same treatment group. Within group differences,
paired samples t-test:
sP!0.05.
aFive subjects were excluded due to negative or extremely high values.
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and glucose tolerance
Mean (S.D.) weight reduction in the merged surgery and
lifestyle groups was 30 (8) % and 9 (10) % respectively
(P!0.001). Self-reported energy intake was signi-
ﬁcantly lower after surgical treatment than after
lifestyle intervention (NGT and AGT groups combined:
from 11.8 (5.1) to 6.9 (1.8) MJ/day and from 12.0 (3.6)
to 8.6 (1.9) MJ/day respectively, P!0.001). At baseline,
none of the participants used hypoglycaemic agents,
whereas three patients who chose surgery and two
patients who chose lifestyle intervention were taking
weight loss medications. After surgery, neither hypogly-
caemic nor weight loss medications were used. By
contrast, after 1 year of lifestyle intervention, ﬁve
patients used hypoglycaemic agents (metformin) and
three patients were taking weight loss medication. AGT
was resolved in all gastric bypass surgery patients
and in 41% (9 out of 22) of lifestyle intervention
patients (P!0.001).
Glucose, insulin and C-peptide during
the OGTT
With the exception of no change in glucose and an
increase in insulin and C-peptide at 30 min after
surgical treatment, both interventions resulted in a
reduction in glucose, insulin and C-peptide at all time
points in both glucose tolerance groups (Fig. 1). At
1 year, glucose, insulin and C-peptide in the surgery
groups were lower at 0 and 120 min and higher at
30 min than in the lifestyle groups. Post challenge
hypoglycaemia (!2.8 mmol/l) was signiﬁcantly more
prevalent after surgical treatment than after lifestyle
intervention (NGT and AGT groups combined: 23 vs
4%, PZ0.002), but did not differ signiﬁcantly between
the NGT and AGT groups (PZ0.768).
Insulin sensitivity and insulin secretion
HOMA-S increased after both interventions, though to a
greater extent in the NGT and AGT surgery groups
than in the corresponding lifestyle groups (Table 1).
The changes in the three indices estimating insulin
secretion during the OGTT yielded diverging results.
While total AUCIns/Gluc and ﬁrst phaseest decreased or
tended to decrease after both interventions in both
glucose tolerance groups, the opposite was the case for
DIns30/DGluc30 (Table 1).
Disposition index
Pairing HOMA-S with the indices of insulin secretion
in subjects with NGT at baseline (nZ96) showed that
the combination of HOMA-S and ﬁrst phaseest was
closest to forming a hyperbola: HOMA-S and ﬁrst
phaseest (bZK0.869, 95% CI (K0.971 to K0.766),
nZ94); HOMA-S and total AUCIns/Gluc (bZK0.796,
95% CI (K0.922 to K0.671, nZ94); and HOMA-S and
DIns30/DGluc30 (bZK0.515 95% CI (K0.697 to
K0.334), nZ90). This combination was therefore
used when calculating the DI presented.
Figure 2A and B depict the 1 year changes in ﬁrst
phaseest and HOMA-S according to glucose tolerance
status at baseline in the surgically and conservatively
treated groups. The ﬁrst phaseest in relation to HOMA-S
shifted to the right after treatment in both the surgery
and lifestyle groups. These ﬁndings are consistent with
increased insulin secretion relative to insulin sensitivity
after both interventions as veriﬁed by increased DI in
subjects with NGT and AGT in the surgery and lifestyle
groups (Fig. 2C). However, the DI increased signiﬁcantly
more after surgical treatment than after lifestyle
intervention in both glucose tolerance groups (Fig. 2C).
Notably, at 1 year, the DI in the NGT surgery group was
even higher than in NGT controls (P!0.001).
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Figure 1 Mean glucose, insulin and
C-peptide during the OGTT in controls and
in morbidly obese subjects at baseline and
1 year after gastric bypass surgery and
intensive lifestyle intervention according to
glucose tolerance status at baseline. Error
bars represent 95% CIs. Independent
samples t-tests were used for the compari-
son of means. *P!0.05, controls versus
intervention groups.
†P!0.05, surgery
versus lifestyle group.
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calculating the alternative DI yielded similar results to
those described above (data not shown).
PI/I ratios
The reduction in stimulated PI/I ratio was greatest
after surgical treatment and was most pronounced
among those with AGT (Fig. 3A). Fasting PI/I ratio
was signiﬁcantly reduced only in surgically treated
patients with AGT (Fig. 3B). Bycontrast, stimulated and
fasting PI/I ratios changed signiﬁcantly neither in the
N G Tg r o u pn o ri nt h eA G Tg r o u pa f t e rl i f e s t y l e
intervention. At 1 year, stimulated PI/I ratio in the
NGT surgery group was even lower than in the NGT
control group (PZ0.027).
Predictors of improved beta cell function
Inthe wholestudypopulation, percentage weightchange
was correlated with both change in DI (rZK0.56,
P!0.001) and change in stimulated PI/I ratio (rZ0.29,
PZ0.001). Furthermore, there was a signiﬁcant corre-
lation between change in DI and change in stimulated
PI/I ratio (rZK0.31, PZ0.001). The changes in
fasting and stimulated PI/I ratios were moderately
correlated (rZ0.41, P!0.001), whereas changes in
fasting PI/I ratio correlated with neither weight nor
DI changes.
The multiple linear regression analyses showed that
i) treatment choice remained associated with change in
DI (bZ0.337, PZ0.008) and stimulated PI/I ratio
(bZK0.339, PZ0.022); ii) glucose tolerance status
at baseline remained associated with change in
stimulated PI/I ratio (bZK0.297, PZ0.002); and
iii) weight change remained associated with change in
DI (bZK0.329, PZ0.008) but not with change in
stimulated PI/I ratio (bZK0.027, PZ0.849).
Discussion
The aim of the present study was to compare the effects
of Roux-en-Y gastric bypass and ILI on beta cell function
in morbidlyobese patients. Our results demonstrate that
insulin sensitivity-adjusted insulin secretion was signi-
ﬁcantly greater after gastric bypass than after lifestyle
intervention. In addition, signiﬁcant reductions in PI/I
ratios in the surgery groups were observed.
Strengths and weaknesses of the study
The main strength of the study is the controlled design.
The limitations are the use of OGTT-derived indices not
validated in gastric bypass-operated patients, the use of
indices for the calculation of DI which did not fully
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bypass and lifestyle intervention. The curve represents the
regression line of the natural logarithm of estimated insulin
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corresponding disposition indices. Error bars represent 95% CIs.
*P value for the effect of treatment choice and glucose tolerance
status at baseline on change in disposition index, two-way ANOVA.
†P!0.05,
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‡P!0.001, between group (surgery versus lifestyle),
changes in disposition index within the same glucose tolerance
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and baseline value.
§P!0.001, normal glucose tolerance versus
abnormal glucose tolerance within the same intervention group
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of gut hormone analyses, the non-randomised design
and the inclusion of predominantly white subjects.
Comparison with other studies
In line with the Diabetes Prevention Programme (8) and
two smaller weight loss studies (6, 7), we conﬁrm that
lifestyle intervention is associated with improved insulin
sensitivity-adjusted insulin secretion. A positive effect of
weight reduction on beta cell function has also been
shown in a longitudinal study in Pima Indians (24).
Contrasting previous results and the results of the
present study, DI did not increase after 24 months of
lifestyle intervention in a study of Japanese Americans
with IGT (9). Since the improvement in insulin secretion
may be proportional to the amount of weight loss (24),
these differences may partly be explained by a modest
weight reduction (2.6%) in the latter study (9). This
notion is further supported by our own results, which
demonstrate that improvement in DI is partly explained
by weight reduction. Furthermore, increased DI after
gastric bypass is in line with some previous studies
addressing insulin secretion after bariatric surgery
in subjects with various degrees of glucose tolerance
(11, 12). However, in contrast with our ﬁndings,
Morinigo et al. (10) failed to demonstrate an increase
in insulin secretory capacity to i.v. glucose in subjects
with NGT or IGT 1 year after gastric bypass when
accounting for prevailing insulin sensitivity. This
discrepancy might have several explanations. First, we
included a higher number of patients than Morinigo
et al., and, second, our use of an OGTT-derived DI may
have yielded a greater increase in the DI (11).
The pattern of change in the DI calculated by total
AUCIns/Gluc and HOMA-S resembled that of the DI based
on ﬁrst phaseest and HOMA-S in all groups. This may
indicate that both early and late phase insulin section
increased after both treatments.
A decrease in both fasting and stimulated PI/I ratios
in the AGT surgery group further supports improved
beta cell function after gastric bypass. The results are
also partly in line with some (12, 25), but not all (26),
previous studies reporting reduced fasting PI/I ratio
after bariatric surgery in morbidly obese subjects with
NGTand AGT. To the best of our knowledge, the possible
effect of gastric bypass on stimulated PI/I ratio has not
been reported previously. Our ﬁnding of a greater
reduction in the PI/I ratios in subjects with AGT than
in those with NGT may indicate that the improvement
in insulin processing after gastric bypass is greatest in
those who need it the most. By contrast, no signiﬁcant
reductions in the PI/I ratios were observed in both the
NGT and the AGT groups after lifestyle intervention.
However, the results correspond with those of a study
reporting no reduction in fasting PI/I ratio in obese
women with type 2 diabetes after diet induced weight
loss (25).
Overall beta cell function was ameliorated to a
greater extent after gastric bypass surgery than after
lifestyle intervention. Since improvement in DI was
independently associated with weight reduction,
greater weight loss in the surgery groups than in the
lifestyle groups could clearly explain some of the
differences. However, it should be noted that surgical
treatment also independently predicted improvements
in DI and that improvements in stimulated PI/I ratio
was associated with surgical treatment and not with
weight reduction. The latter ﬁndings indicate that the
improvements in beta cell function may be partly
related to the surgical procedure per se and not only to
weight reduction.
One year after surgery, post challenge glucose, insulin
and C-peptide dropped sharply after an initial rise, with
12
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in both glucose tolerance groups. Specially worth
noting is the high prevalence of post challenge
hypoglycaemia. As demonstrated in this and previous
studies, excessive insulin secretion may occur after
gastric bypass (13, 25). Although the present study was
not designed to explore the pathophysiological
mechanisms for post bypass hyperinsulinaemia, it
might be speculated that bypassing the gastric ventricle
causes rapid absorption of glucose and consequently
high glucose levels immediately after glucose ingestion.
Indeed, we and others (13, 25) have reported elevated
glucose levels 30 min after a glucose load in gastric
bypass patients. Hyperglycaemia may in turn stimulate
insulin secretion and thereby contribute to the observed
hyperinsulinaemia. However, it is also very likely that
other factors are involved, with a few publications
recently addressing this phenomenon (13, 14). Some
researchers argue that post-gastric bypass hyperinsuli-
naemia may be explained by the increase in gut
hormones such as glucagon-like peptide 1 (GLP1) and
gastric inhibitory peptide, which follows the rearrange-
ment of the intestine (13, 25). Alternatively, but not
mutuallyexclusive,pathologic overgrowthof pancreatic
beta cells, possibly stimulated by GLP1, after bypass
surgery may result in hypersecretion of insulin (14).
Finally, improved glycaemic control caused by
enhanced insulin sensitivity after weight loss may in
turn reduce the toxic effect of glucose on the pancreatic
beta cells and thereby increase insulin secretion. This
would partly explain the improved beta cell function
observed after lifestyle intervention in both the present
study and others like it (6–8).
Conclusions
In summary, beta cell function improved in subjects
with both NGT and AGT after both interventions,
although this was more pronounced after Roux-en-Y
gastric bypass. Notably, supra-physiological insulin
secretion and proinsulin processing may point towards
excessive beta cell function after gastric bypass surgery.
This may possibly contribute to improved glycaemic
control in patients with AGT but also to postprandial
hypoglycaemia observed after this procedure.
Future studies addressing the same themes should be
longitudinal, use both i.v. and oral techniques for
the estimation of beta cell function and include
gut hormones.
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